"Provide a new potent brachytherapy tool for the treatment of cancers in
humans and animals that will be very effective in improving the lives of
The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and
approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market
sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private
veterinary clinic consortiums.
you can edit this section directly in HTML ( templates > custom template > html )
Vivos Inc Extends it Intellectual Property Protection
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search
Report on our patent application (No.1811.191).
We are excited to report that seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the
patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet® and Radiogel™. As part of the normal review process, we have also submitted the technical justification for seven additional claims
and are confident these additional claims will prevail.
This month we will file patent claims in Canada, UK (Great Britain, Scotland, Wales and Ireland), Japan, Germany, Italy, France, Australia, Brazil, China, India, North Countries (Sweden, Norway,
Finland, and Denmark).